ConductScience.org, home

Paper12960733

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

van Kesteren Ch and 6 others. Anticancer Drugs, 2003. Cited by 65 papers, by iCite.

Cite this record

ConductScience Library. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Papers, record 12960733. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12960733

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
PubMed
Journal
Anticancer Drugs
PubMed
Year
2003
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
65
iCite
Relative citation ratio, by iCite
1.6
iCite
Revised in PubMed
2022-03-16
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1van Kesteren ChCh
2de Vooght MMM M M
3López-Lázaro LL
4Mathôt RAR A A
5Schellens JHJ H M
6Jimeno JMJ M
7Beijnen JHJ H

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, AlkylatingMajor topic
DioxolesMajor topic
IsoquinolinesMajor topic
NeoplasmsMajor topic
Animals
Cell Cycle
Chemistry, Pharmaceutical
Clinical Trials as Topic
Female
Humans
Tetrahydroisoquinolines
Trabectedin

Source PubMed

Download CSV of topics

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.

PMIDTitleJournalYearIn PapersSource
42356528Natural Products as Promising Pharmacological Agents Against Cancer: A Holistic Overview of Their Anti-Cancer Mechanisms of Action of the Last Five Years.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42356528PubMed
41745729The Cardioprotective Potential of Marine Venom and Toxins.Toxins (Basel)2026https://conductscience.org/library/papers/41745729PubMed
39797969Didemnins as marine-derived anticancer agents: mechanistic insights and clinical potential.Med Oncol2025https://conductscience.org/library/papers/39797969PubMed
39450552Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).Int J Mol Med2025https://conductscience.org/library/papers/39450552PubMed
39228518Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin.Front Pharmacol2024https://conductscience.org/library/papers/39228518PubMed
32500752PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.Expert Opin Drug Metab Toxicol2020https://conductscience.org/library/papers/32500752PubMed
31782213Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer.Med Res Rev2020https://conductscience.org/library/papers/31782213PubMed
31621891Enriching cancer pharmacology with drugs of marine origin.Br J Pharmacol2020https://conductscience.org/library/papers/31621891PubMed
31482373Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells.Invest New Drugs2020https://conductscience.org/library/papers/31482373PubMed
31208455An appraisal of natural products active against parasitic nematodes of animals.Parasit Vectors2019https://conductscience.org/library/papers/31208455PubMed
30366467Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line.Cells2018https://conductscience.org/library/papers/30366467PubMed
29449896Myxofibrosarcoma primary cultures: molecular and pharmacological profile.Ther Adv Med Oncol2017https://conductscience.org/library/papers/29449896PubMed
29292724Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.Int J Mol Sci2017https://conductscience.org/library/papers/29292724PubMed
28794805Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Ther Adv Med Oncol2017https://conductscience.org/library/papers/28794805PubMed
27541923Clinical Implications of Sarcopenic Obesity in Cancer.Curr Oncol Rep2016https://conductscience.org/library/papers/27541923PubMed
26921498Small-molecule modulators of PXR and CAR.Biochim Biophys Acta2016https://conductscience.org/library/papers/26921498PubMed
25614221The re-emergence of natural products for drug discovery in the genomics era.Nat Rev Drug Discov2015https://conductscience.org/library/papers/25614221PubMed
25252616Pregnane X receptor and drug-induced liver injury.Expert Opin Drug Metab Toxicol2014https://conductscience.org/library/papers/25252616PubMed
21523334Emerging therapeutic targets for soft tissue sarcoma.Curr Oncol Rep2011https://conductscience.org/library/papers/21523334PubMed
19238326Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.Invest New Drugs2010https://conductscience.org/library/papers/19238326PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12960733

GET https://conductscience.org/api/papers/v1/12960733/cited_by?page=2